OakChart

Autonomix Medical Inc

AMIXHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 9:30 AM ET

1.66-0.19 (-10.00%)
2026-11-11 15:31 CET
Market cap
3.63 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-11.78 USD m
Free cash flow, TTM
-12.04 USD m
EPS diluted, TTM
-20.08
P/E
-
Compare

Price

AMIX against its 20, 50 and 200-day averages
2050200beatmiss
10.0020.0060.0M120.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AMIXclose 1.6720-day 2.0950-day 3.20200-day 6.471.67

94.9% under 32.55 on 17 Nov 2025. Last 15 sessions, 126.0% high to low

Profile

AMIX
52-week range, 1% of the way up
1.4632.55

Autonomix Medical, Inc. is a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies. The company was founded by Robert Schwartz, Landy Toth, David A. Robins, and Robert A. Van Tassel on June 10, 2014 and is headquartered in The Woodlands, TX.

IPOJan 29, 2024
Beta-0.78
ATR, 14d0.33
Rel volume3.41
Short float3.02%
Insider own5.90%
Inst own5.08%

Snapshot

6 groups

Valuation

Index-
Market Cap3.27M
Enterprise Value-4.42M
Income-11.78M
Sales0.00M
Book/sh3.54
Cash/sh3.92
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOJan 29, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.47
P/C0.42
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio6.52
Current Ratio6.52
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-20.08
EPS next Y-8.60
EPS next Q-2.62
EPS this Y-
EPS next Y-
EPS next 5Y69.24%
EPS past 3/5Y-3.02% 35.84%
Sales past 3/5Y- -
EPS Y/Y TTM64.78%
Sales Y/Y TTM-
EPS Q/Q91.33%
Sales Q/Q-
EarningsSep 02
EPS/Sales Surpr.0.00% -

Ownership

Insider Own5.90%
Insider Trans0.00%
Inst Own5.08%
Inst Trans6.66%
ROA-146.10%
ROE-176.02%
ROIC-169.73%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-20.53%
SMA50-47.89%
SMA200-74.25%
Trades-

Technical

Shs Outstand1.96M
Shs Float1.84M
Short Float3.02%
Short Ratio0.03
Short Interest0.06M
52W High32.55 -94.88%
52W Low1.46 14.04%
Volatility30.98% 13.22%
ATR (14)0.33
RSI (14)28.70
Beta-0.78
Rel Volume3.41
Avg Volume1.96M
Volume333,995

Performance

Perf Week3.42%
Perf Month-44.68%
Perf Quarter-75.73%
Perf Half Y-75.94%
Perf YTD-85.58%
Perf Year-90.66%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price6.00
Prev Close1.85
Price1.66
Change %-10.00%

Peers

Mkt cap
TickerCompanyMkt cap
ADGMAdagio Medical Holdings Inc1.68M
BDMDBaird Medical Investment Holdings Limited3.56M
ICCMIcecure Medical Ltd2.74M
CVRXCVRx Inc20.23M
TLSITriSalus Life Sciences Inc166.56M
NSPRInspireMD Inc36.26M
ECORElectroCore Inc73.62M
DCTHDelcath Systems Inc700.01M
NXLNexalin Technology Inc1.69M
STXSStereotaxis Inc87.21M

News

latest 14 of 206
  • Autonomix Medical Granted New U.S. Patent Strengthening Proprietary Catheter-Based Sensing Technology (GlobeNewswire) +8.82%
  • Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation (GlobeNewswire)
  • Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance (GlobeNewswire)
  • Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform (GlobeNewswire)
  • Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors (GlobeNewswire)
  • Loading…
  • Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026 (GlobeNewswire)
  • Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery (GlobeNewswire) -11.27%
  • Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules (GlobeNewswire) +33.89%
  • Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission (GlobeNewswire) -17.38%
  • Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award (GlobeNewswire) -7.47%
  • Autonomix Medical Receives U.S. Patent for Precision Neuromodulation Platform Expansion (InvestorsHub) +434.25%
  • Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy (GlobeNewswire)
  • Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study (GlobeNewswire) -16.57%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q12026-09-02-6.405-6.405-5.0180.000.002
2025Q42026-06-03-4.830-4.830-4.9070.000.002
2025Q32026-02-25-7.560-7.560-7.6470.00-1
2025Q22025-11-10-28.980-31.500-28.9130.000.001
2025Q12025-09-03-22.470-18.585-22.5680.000.002
2024Q42025-05-28-38.535-25.935-26.8360.000.002
2024Q32025-02-26-30.660-30.660-30.7530.000.001
2024Q22024-11-12-51.8700.000-51.8240.000.001
2024Q12024-08-28-58.800--59.9720.00--
2026Q2---2.620---1
2026Q3---1.640---1
2026Q4---1.570---1
2027Q1---5.460--0.001
2027Q2---5.460--0.001
2027Q3---4.830--0.001
2027Q4---4.620--0.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-211.05--343.780.00-
2024FY-135.66-83.055-135.660.000.00
2025FY-48.720-48.720-48.7200.000.00
2026FY--22.680--0.00
2027FY--19.530--0.00
2028FY--17.430--1.75
2029FY--12.390--11.62
2030FY--3.780--29.27

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q2S2026-09-021000.000.000.00
2026Q2S2026-06-031000.000.000.00
2026Q2S2026-05-291000.000.000.00
2026Q2S2025-11-011000.000.000.00
2026Q2S2025-10-311000.000.000.00
2026Q2S2025-10-301000.000.000.00
2026Q2S2025-10-291000.000.000.00
2026Q2S2025-10-281000.000.000.00
2026Q2S2025-10-271000.000.000.00
2026Q2S2025-10-261000.000.000.00
2026Q2S2025-10-251000.000.000.00
2026Q2S2025-10-241000.000.000.00
2026Q2S2025-10-231000.000.000.00
2026Q2S2025-10-221000.000.000.00

Estimate history

EPS, annual-286.982-44.482-343.783-135.647-48.639-20.0773
Period20212022202320242025TTM
EPS, quarterly-51.824-30.753-26.836-22.568-28.913-7.647-4.907-5.018-2.506
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000000
Period20212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0450.0450.0450.1190.5431.96
Period20212022202320242025MRQ
Shares, quarterly0.0550.1170.1190.1920.2950.5430.5430.5421.96
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.180.080.000.00
Gross Profit-0.01-0.01-0.18-0.080.000.00
Selling, General and Administrative Excl. Other12.0117.0211.407.391.9913.59
Research and Development6.287.144.722.230.660.00
Other Operating Expense0.000.000.000.000.000.00
Operating Income-12.03-17.03-11.59-7.47-1.99-13.59
Interest Expense0.000.000.180.080.000.22
Unusual Expense0.000.000.008.000.00-0.48
Net Income Before Taxes-11.78-16.71-11.41-15.43-1.99-13.33
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-11.78-16.71-11.41-15.43-1.99-13.33
Net Income From Continuing Operations-11.78-16.71-11.41-15.43-1.99-13.33
Net Income-11.78-16.71-11.41-15.43-1.99-12.84
EPS (Recurring)-9.44-48.64-135.65-218.98-44.48-294.55
EPS (Basic, Before Extraordinaries)-20.08-48.64-135.65-343.78-44.48-286.98
EPS (Diluted)-20.08-48.64-135.65-343.78-44.48-286.98
EBITDA-12.01-17.02-11.40-7.39-1.99-13.59
Non-Operating Income (Expense)0.250.320.350.130.000.00
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense0.060.531.630.62-0.30
Shares Outstanding1.960.540.120.040.040.04
Market Capitalization3.633.634.3756.7656.76-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.050.05
Gross Profit-0.00-0.00-0.00-0.00-0.00-0.00-0.05-0.05
Selling, General and Administrative Excl. Other3.172.772.733.347.533.423.202.70
Research and Development1.581.511.461.722.371.591.551.04
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.18-2.77-2.74-3.34-7.53-3.42-3.25-2.75
Interest Expense0.000.000.000.000.000.000.050.04
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-3.13-2.73-2.67-3.26-7.45-3.34-3.19-2.71
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-3.13-2.73-2.67-3.26-7.45-3.34-3.19-2.71
Net Income From Continuing Operations-3.13-2.73-2.67-3.26-7.45-3.34-3.19-2.71
Net Income-3.13-2.73-2.67-3.26-7.45-3.34-3.19-2.71
EPS (Recurring)-2.51-5.02-4.91-7.65-28.91-22.57-26.84-30.75
EPS (Basic, Before Extraordinaries)-2.51-5.02-4.91-7.65-28.91-22.57-26.84-30.75
EPS (Diluted)-2.51-5.02-4.91-7.65-28.91-22.57-26.84-30.75
EBITDA-3.17-2.77-2.73-3.34-7.53-3.42-3.20-2.70
Non-Operating Income (Expense)0.050.040.070.080.080.080.110.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.050.000.000.000.140.390.410.42
Shares Outstanding1.960.540.540.540.290.190.120.12
Market Capitalization3.633.384.456.286.696.324.379.26

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments7.009.148.610.862.04
Short Term Receivables0.000.000.000.000.00
Inventories0.000.000.000.000.00
Other Current Assets0.580.470.780.000.01
Total Current Assets7.589.619.390.862.05
Net Property, Plant & Equipment0.020.020.020.000.00
Total Investments and Advances0.000.000.000.000.00
Intangible Assets0.000.000.000.000.00
Other Assets0.000.180.000.000.00
Total Assets7.609.819.410.862.05
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.00
Accounts Payable0.700.680.490.170.09
Other Current Liabilities1.001.030.280.050.00
Total Current Liabilities1.711.710.780.220.09
Long Term Debt0.000.001.000.000.00
Provision for Risks Charges0.000.000.000.000.00
Other Liabilities0.000.000.000.000.00
Total Liabilities1.711.711.780.220.09
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity5.898.107.630.641.96
Total Shareholders Equity5.898.107.630.641.96
Accumulated Minority Interest0.000.000.000.000.00
Total Equity5.898.107.630.641.96
Total Liabilities & Stockholders Equity7.609.819.410.862.05
Book Value Per Share10.8568.11170.0014.3943.79
Tangible Book Value Per Share10.8568.11170.0014.3943.79
Full-Time Employees-1185-
Price to Book Ratio0.320.54-10.14-10.14-
Return on Assets-192.06-118.77-300.36-136.46-
Return on Equity-238.89-145.10-372.97-152.91-
Return on Invested Capital-283.55-140.88-178.75-309.07-680.21
Quick Ratio4.455.6312.093.9222.02
Current Ratio4.455.6312.093.9222.02

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-11.78-16.71-11.41-15.43-1.99-13.33
Depreciation0.010.010.180.08--
Other Funds (Non Cash)0.064.531.738.620.0012.74
Funds from Operations-11.71-12.18-9.50-6.73-1.99-0.59
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.31-0.111.240.080.140.20
Cash from Operating Activities-12.02-12.28-8.26-6.65-1.85-0.39
Capital Expenditures-0.02-0.01-0.01-0.020.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.02-0.01-0.01-0.020.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock-0.212.618.8012.410.681.89
Repurchase of Common Pref Stock-0.010.000.000.000.000.00
Sale of Common Pref Stock-0.202.618.8012.410.681.89
Proceedsfrom Stock Options-0.202.618.8012.410.681.89
Issuance or Reduction of Debt, Net0.000.000.002.000.000.54
Change in Long Term Debt0.000.000.002.000.000.54
Issuance of Long Term Debt0.000.000.002.000.000.54
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow12.467.550.000.000.000.00
Other Financing Activities Uses-0.040.000.000.000.000.00
Cash from Financing Activities12.2510.168.8014.410.682.43
Net Change in Cash0.21-2.130.537.74-1.182.04
Free Cash Flow-12.04-12.29-8.27-6.67-1.85-0.39
Preferred Dividends (Cash Flow)-0.000.000.000.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments7.693.467.009.937.488.59
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.480.500.580.260.420.39
Total Current Assets8.183.967.5810.197.898.98
Net Property, Plant & Equipment0.020.020.020.020.020.02
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.020.00
Total Assets8.203.987.6010.217.939.00
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.630.370.700.710.840.81
Other Current Liabilities0.620.451.000.940.651.15
Total Current Liabilities1.250.821.711.651.491.97
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities1.250.821.711.651.491.97
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity6.943.165.898.566.457.03
Total Shareholders Equity6.943.165.898.566.457.03
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity6.943.165.898.566.457.03
Total Liabilities & Stockholders Equity8.203.987.6010.217.939.00
Book Value Per Share3.545.8310.8515.7621.8536.71
Tangible Book Value Per Share3.545.8310.8515.7621.8536.71
Price to Book Ratio0.320.570.760.731.040.90
Return on Assets-146.10-248.22-192.06-155.57-250.94-149.73
Return on Equity-176.02-315.99-238.89-188.75-352.39-195.55
Return on Invested Capital-45.04-86.27-45.22-38.09-115.61-47.45
Quick Ratio6.524.854.456.185.314.57
Current Ratio6.524.854.456.185.314.57

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-3.13-2.73-2.67-3.26-7.45-3.34
Depreciation0.000.000.000.000.000.00
Other Funds (Non Cash)0.050.000.000.004.200.32
Funds from Operations-3.07-2.72-2.66-3.25-3.25-3.01
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.46-0.82-0.230.29-0.510.34
Cash from Operating Activities-2.61-3.54-2.89-2.97-3.75-2.67
Capital Expenditures-0.010.00-0.00-0.010.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.010.00-0.00-0.010.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.610.00-0.040.430.102.12
Repurchase of Common Pref Stock-0.010.000.000.000.000.00
Sale of Common Pref Stock-0.600.00-0.040.430.102.12
Proceedsfrom Stock Options-0.600.00-0.040.430.102.12
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow7.460.000.005.002.550.00
Other Financing Activities Uses-0.040.000.000.000.000.00
Cash from Financing Activities6.850.00-0.045.432.642.12
Net Change in Cash4.23-3.54-2.932.46-1.11-0.55
Free Cash Flow-2.62-3.54-2.90-2.98-3.75-2.67

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.02%0.1M1.8M2.99M
2026-10-153.21%0.1M1.8M4.39M
2026-09-301.55%0.0M1.7M4.46M
2026-09-153.55%0.1M1.7M4.51M
2026-08-313.29%0.1M1.8M4.43M
2026-08-1411.45%0.1M1.0M3.77M
2026-07-3129.27%0.3M0.9M1.55M
2026-07-1512.33%0.1M0.5M85.91K
2026-06-303.30%0.0M0.5M37.13K
2026-06-153.16%0.0M0.5M33.24K
2026-05-295.94%0.0M0.5M33.81K
2026-05-151.80%0.0M0.5M6.74K
2026-04-302.12%0.0M0.5M7.53K
2026-04-151.60%0.0M0.5M9.05K
2026-03-312.08%0.0M0.5M47.97K
2026-03-131.91%0.0M0.5M158.18K
2026-02-272.89%0.0M0.5M156.20K
2026-02-134.65%0.0M0.5M400.31K
2026-01-309.09%0.0M0.3M399.80K
2026-01-1510.32%0.0M0.3M393.29K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-10-29SEC
2026-10-133Initial statement of beneficial ownership of securities2026-09-14SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-16424B3SEC
2026-09-168-KCurrent report2026-09-14SEC
2026-09-15EFFECTEffectiveness filing by commission orderSEC
2026-09-14DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-14DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-29SEC
2026-09-11424B5SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-04PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-29SEC
2026-09-04S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-268-KCurrent report2026-08-24SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-04EFFECTEffectiveness filing by commission orderSEC
2026-07-31424B5SEC
2026-07-28S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-07-288-KCurrent report2026-07-28SEC
2026-07-158-KCurrent report2026-07-13SEC
2026-07-108-KCurrent report2026-07-09SEC
2026-06-248-KCurrent report2026-06-18SEC
2026-06-1510-K/A2026-03-31SEC
2026-05-2710-KAnnual report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-02S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-02-1110-QQuarterly report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-01-168-KCurrent report2026-01-14SEC
2026-01-098-KCurrent report2026-01-09SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Mariner, LLC9.23%
GEODE CAPITAL MANAGEMENT, LLC2.48%
Allied Private Wealth LLC0.06%
Tower Research Capital LLC0.06%
PNC FINANCIAL SERVICES GROUP, INC.0.00%
Caitong International Asset Management Co., Ltd0.00%
Investors Research Corp0.00%
Networth Advisors, LLC0.00%
CITIGROUP INC0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund3.59%
Fidelity Extended Market Index Fund1.40%
Fidelity Total Market Index Fund0.01%

OakChart. AMIX. Cached 15 minutes.

Some panels did not load: ratings, insider.